The total acquistion value is considered to be $312m and around $114m based on certain pre-determined milestones which also includes revenue targets.
As of 31March 2012, US-based OraPharma’s net revenue was nearly $95m.
The deal which is subject to the satisfaction of certain closing conditions, is expected to close in June 2012.
Valeant Pharmaceuticals chairman and chief executive officer J. Michael Pearson said,"We are excited to enter a new attractive market segment with an already established sales infrastructure focused entirely on the dental community."